Concepedia

Chris L. Navas

CL

Statistics

Publications

1

Citations

60

H-Index

1

Active since

2022

Affiliations

Lyell Immunopharma (United States)(Current)

Chris L. Navas is an author at Lyell Immunopharma (United States) specializing in cd28 signaling, cancer immunology, and dual checkpoint inhibition.

Publications per year

2022–2022

1

Publications

1

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

Mark Maurer, Katherine E. Lewis, Joseph L. Kuijper et al. · Nature Communications · 2022 · 60 citations · Full text

Life Sciences, Immunology, Oncology +17

1–1 of 1